Journal
CELLS
Volume 11, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/cells11081316
Keywords
TGF-beta 1; fibroblast; myofibroblast; fibrosis; COVID-19
Categories
Ask authors/readers for more resources
Cardiovascular disease is the leading cause of death worldwide, and patients with cardiovascular diseases are more susceptible to severe complications of COVID-19. The role of cardiac myofibroblasts in both COVID-19-induced cardiac injury and healing process is crucial.
Cardiovascular disease (CVD) is the leading cause of death worldwide. Current data suggest that patients with cardiovascular diseases experience more serious complications with coronavirus disease-19 (COVID-19) than those without CVD. In addition, severe COVID-19 appears to cause acute cardiac injury, as well as long-term adverse remodeling of heart tissue. Cardiac fibroblasts and myofibroblasts, being crucial in response to injury, may play a pivotal role in both contributing to and healing COVID-19-induced cardiac injury. The role of cardiac myofibroblasts in cardiac fibrosis has been well-established in the literature for decades. However, with the emergence of the novel coronavirus SARS-CoV-2, new cardiac complications are arising. Bursts of inflammatory cytokines and upregulation of TGF-beta 1 and angiotensin (AngII) are common in severe COVID-19 patients. Cytokines, TGF-beta 1, and Ang II can induce cardiac fibroblast differentiation, potentially leading to fibrosis. This review details the key information concerning the role of cardiac myofibroblasts in CVD and COVID-19 complications. Additionally, new factors including controlling ACE2 expression and microRNA regulation are explored as promising treatments for both COVID-19 and CVD. Further understanding of this topic may provide insight into the long-term cardiac manifestations of the COVID-19 pandemic and ways to mitigate its negative effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available